Column Capital Advisors’s Epizyme, Inc EPZM Stock Holding History

Column Capital Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-248	Closed	-$6K	–	815
2019 Q4	$6K	Buy	+248	New	+$3.68K	﹤0.01%	520

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Column Capital Advisors's EPZM Position: Q1 2020 in Review

Column Capital Advisors sold out of Epizyme, Inc (EPZM) in Q1 2020, closing a stake of 248 shares — an estimated $6K sold.

Column Capital Advisors first reported a position in EPZM in Q4 2019 and held it in 1 quarter. The position peaked at $6K in Q4 2019. 143 funds tracked by Wall St. Rank hold EPZM as of Q1 2020.

Column Capital Advisors reported no remaining Epizyme, Inc position as of Q1 2020 after selling out during the quarter.
Column Capital Advisors sold 248 Epizyme, Inc shares in Q1 2020, an estimated $6K.
Column Capital Advisors first reported a position in Epizyme, Inc in Q4 2019 and held it in 1 quarter.
Column Capital Advisors's Epizyme, Inc position peaked at $6K in Q4 2019.
143 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2020.

Based on Column Capital Advisors's 13F filing for Q1 2020, filed 11 May 2020.